Nivashnee Naicker
Biographic Data
| ID | 7730641 |
|---|---|
| NAME | Nivashnee Naicker |
| GIVEN NAMES | Nivashnee |
| FAMILY NAME | Naicker |
| SIGNATURE | NAICKER N |
| AFFILIATIONS | Centre for the AIDS Programme of Research in South Africa |
| ORCID | 0000-0002-8819-3825 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2015 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…
Acceptability of Early Antiretroviral Therapy Among South African Women
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting
No prominent works on this page.
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting
Acceptability of Early Antiretroviral Therapy Among South African Women
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…
Immunology (3 works) · Internal Medicine (3 works) · Medicine (3 works) · Cohort (2 works) · Cohort study (2 works) · Demography (2 works) · Demography (2 works) · HIV/AIDS Research and Interventions (2 works) · Human immunodeficiency virus (HIV (2 works) · Public health (2 works)